Picture loading failed.

Anti-TGFB1 therapeutic antibody (Pre-made Metelimumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.[1] It was dropped from further development in favour of fresolimumab,[2] which was being developed by Genzyme as of 26.[3]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-908-1mg 1mg 3090
GMP-Bios-INN-908-10mg 10mg Inquiry
GMP-Bios-INN-908-100mg 100mg Inquiry
GMP-Bios-INN-908-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Metelimumab Biosimilar, Whole Mab, Anti-Tgfb1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody
INN Name Metelimumab
TargetTGFB1
FormatWhole mAb
Derivationhuman
Species Reactivityhuman
CH1 IsotypeIgG4 - kappa
VD LCIgG4 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesGenzyme Corp. (Cambridge MA USA) / Cambridge Antibody Technology (Cambridge UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0